Quantum BioPharma Lawsuit Alleging Market Manipulation Featured in CTV W5 Investigation
TL;DR
Quantum BioPharma's lawsuit against CIBC and RBC could expose market manipulation, potentially strengthening its position for advancing Lucid-MS and creating investment opportunities.
Quantum BioPharma alleges stock spoofing through millions of illegal orders from bank platforms, detailed in a CTV W5 segment and a $700 million lawsuit.
By pursuing legal action against alleged market manipulation, Quantum BioPharma aims to protect its development of Lucid-MS, a potential multiple sclerosis treatment that could improve lives.
CTV's W5 aired Part 2 investigating Quantum BioPharma's claims of widespread stock spoofing tied to its $700 million lawsuit against major Canadian banks.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in the second part of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights the company's claims of widespread market manipulation and its impact on Quantum BioPharma's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment.
CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity during the W5 segment, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The company maintains that this alleged market manipulation has directly affected its ability to finance and develop Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The lawsuit represents a significant legal challenge in the financial sector, with Quantum BioPharma alleging that the spoofing activities undermined investor confidence and impacted the company's market valuation. This comes as the company focuses on building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is advancing Lucid-MS while also maintaining other business interests. The company retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, with an agreement that includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc.
The W5 investigation brings increased public attention to allegations of market manipulation in the biopharmaceutical sector, where research and development funding often depends heavily on market performance and investor confidence. The full press release about the W5 segment can be viewed at https://ibn.fm/t3Tex, while the latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The investigative program's coverage of these allegations against major financial institutions highlights ongoing concerns about market integrity and its impact on innovative medical research funding.
Curated from InvestorBrandNetwork (IBN)
